Yahoo Web Search

  1. Hedge Funds Are Undecided About AstraZeneca plc (AZN)

    Insider Monkey via Yahoo FinanceOct 09 20:05 PM

    In this article, we will particularly take a look at what hedge funds think about AstraZeneca plc (NYSE:AZN).

  2. AstraZeneca plc AZN presented detailed data from a phase III study evaluating the company’s and Merck’s MRK PARP inhibitor, Lynparza, as a precision medicine for an advanced prostate ...

  3. AstraZeneca's Triple-Combo COPD Inhaler Gets CRL From FDA

    Zacks via Yahoo FinanceOct 02 11:05 AM

    AstraZeneca plc AZN announced that the FDA has given a complete response letter to its new drug application (NDA) looking for approval of its investigational triple combination ...

  4. AstraZeneca's Fasenra Gets FDA Nod for Self-Administration

    Zacks via Yahoo FinanceOct 07 12:23 PM

    AstraZeneca plc AZN announced that the FDA has approved a self-administration option for its asthma drug, Fasenra (benralizumab) in a new delivery method — a pre-filled, single-use ...

  5. AstraZeneca's (AZN) Lynparza reduces the risk of disease progression by 41% in a study, evaluating the PARP inhibitor as a first-line maintenance treatment in women with advanced ovarian cancer.

  6. The study tested Lynparza in patients as an add-on to an already existing standard of care, bevacizumab, and was compared to a group of patients given bevacizumab alone. The treatment showed ...

  7. AstraZeneca AZN and its Japanese partner Daiichi Sankyo Company announced that the FDA has granted priority review to the biologics license application (“BLA”) for their antibody drug ...

  8. GlaxoSmithKline plc GSK presented positive detailed data from the phase III PRIMA study evaluating its PARP inhibitor, Zejula (niraparib), as monotherapy for maintenance therapy of women ...

  9. Roche Holding AG RHHBY announced that the FDA approved the label expansion of Rituxan (rituximab). The agency approved the drug, in combination with glucocorticoids, for the treatment of two ...

  10. AstraZeneca Plc and Merck & Co Inc said on Monday their treatment for newly diagnosed advanced ovarian cancer improved progression-free survival in patients tested in a late-stage ...